Zhejiang Xianju Pharmaceutical

Company snapshot

Zhejiang Xianju Pharma is a pharmaceuticals company based out of TAIZHOU, ZJ | Zhejiang, China.

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Zhejiang Xianju Pharmaceutical. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Zhejiang Xianju Pharmaceutical.

1. Jun 8, 2026 Clinical update

   0.9% Sodium Chloride, JNJ-78901563 — Phase 3

2. May 26, 2026 Clinical update

   RILPIVIRINE , JNJ-16150108 — Phase 2

View all clinical trial activity →

• What is Zhejiang Xianju Pharmaceutical?

  Xian-Janssen Pharmaceutical is a pharma organization headquartered in 西安, CN. Primary therapeutic focus areas include Invasive Extraintestinal Pathogenic Escherichia coli Disease, HIV-1 Infection. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(

• Is Zhejiang Xianju Pharmaceutical publicly traded?

  Zhejiang Xianju Pharmaceutical appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Zhejiang Xianju Pharmaceutical develop or market?

  We link 5 drug profile(s) where Zhejiang Xianju Pharmaceutical is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/janssen-pharmaceutica-n-v#company-drugs.

• What are the latest developments for Zhejiang Xianju Pharmaceutical?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Zhejiang Xianju Pharmaceutical focus on?

  Zhejiang Xianju Pharmaceutical focuses on Invasive Extraintestinal Pathogenic Escherichia coli Disease, HIV-1 Infection based on our analysis of their pipeline programs and drug development activities.